Justin Klein, MD, JD, is a co-founder and Managing Partner at Vensana Capital, a leading venture capital and growth equity firm dedicated to medtech innovation. Justin currently or previously served on the board of directors of Apella, Cartiva (acquired), ChromaCode, Cleerly, Curate BioSciences, CV Ingenuity (acquired), Epix Therapeutics (acquired), Evident Vascular, Intact Vascular (acquired), Personal Genome Diagnostics (acquired), PhaseBio Pharmaceuticals (IPO), Relievant Medsystems (acquired), Senseonics (IPO), Topera (acquired), Ulthera (acquired), Vertiflex (acquired), Vesper Medical (acquired), and VytronUS (acquired). Justin currently serves as a member of the board of directors of the Medical Device Manufacturers Association and that of AdvaMed Accel, where he is the Vice Chair of the Investor Advisory Committee of AdvaMed’s board. He is also a member of the board of directors of CareFirst BlueCross BlueShield, one of the country’s largest not-for-profit healthcare organizations that serves over 3.5 million patients in the greater Washington, DC, region.

Prior to Vensana, Justin was a partner and leader of the medical technology investing practice at NEA, one of the largest and most active venture capital firms in the world. Justin also worked at the Duke University Health System where his experience included roles in strategy, finance, and operations as Duke built one of the nation’s first integrated healthcare delivery systems.

Justin graduated with an AB in Economics, a BS in Biological Anthropology & Anatomy, and a Minor in Chemistry from Duke University. He also concurrently earned an MD from the Duke University School of Medicine and a JD from Harvard Law School.